EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients

Michele Cicala, Manuele Gori iD, Paola Balestrieri, Annamaria Altomare, Alessandro Tullio, Simone Di Cola iD, Sander Dejongh, Maria Giovanna Graziani, Cristiano Pagnini iD, Simone Carotti iD, Giuseppe Perrone iD, Mentore Ribolsi und 3 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25115817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Michele Cicala und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Fondazione Policlinico Universitario Campus Bio-Medico and Università Campus Bio-Medico di Roma, 00128 Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Permeability, Intestinal Mucosa, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda (Italy), Takeda Italia S.p.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vedolizumab (VDZ) is used for treating inflammatory bowel disease (IBD) patients. A study investigating colonic epithelial barrier function ex vivo following VDZ is lacking. This work aims to evaluate ex vivo the colonic epithelial barrier function in IBD patients at baseline and during VDZ treatment, and to investigate the relationships between barrier function and clinical parameters. Colonic specimens were obtained from 23 IBD patients before, and at 24 and 52 weeks after VDZ treatment, and from 26 healthy volunteers (HV). Transepithelial electrical resistance (TEER, permeability to ions) and paracellular permeability were measured in Ussing chambers. IBD patients showed increased epithelial permeability to ions (TEER, 13.80 ± 1.04 Ω × cm2 vs. HV 20.70 ± 1.52 Ω × cm2, p < 0.001) without changes in paracellular permeability of a 4 kDa probe. VDZ increased TEER (18.09 ± 1.44 Ω × cm2, p < 0.001) after 52 weeks. A clinical response was observed in 58% and 25% of patients at week 24, and in 62% and 50% at week 52, in ulcerative colitis and Crohn’s disease, respectively. Clinical and endoscopic scores were strongly associated with TEER. TEER < 14.65 Ω × cm2 predicted response to VDZ (OR 11; CI 2–59). VDZ reduces the increased permeability to ions observed in the colonic epithelium of IBD patients before treatment, in parallel to a clinical, histological (inflammatory infiltrate), and endoscopic improvement. A low TEER predicts clinical response to VDZ therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPermeabilityIntestinal MucosaInflammatory Bowel DiseasesColonHumansMaleFemaleAdultMiddle AgedIonsGastrointestinal AgentsElectric ImpedanceColitis, UlcerativeCrohn DiseaseAged

Stichwörter der Autor:innen

Ussing chamberscolonic epithelial permeabilityinflammatory bowel diseaseintegrin-receptor antagonistintestinal barrier functiontransepithelial electrical resistance

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabIonsGastrointestinal Agents

Autor:innen und Institutionen

  • Gastroenterology Unit, Fondazione Policlinico Universitario Campus Bio-Medico and Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), International Campus "A. Buzzati-Traverso", Via E. Ramarini 32, Monterotondo Scalo, 00015 Rome, Italy.
  • Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
  • Laboratory of Nephrology and Renal Transplantation, KU Leuven, 3000 Leuven, Belgium.
  • Department of Gastroenterology and Digestive Endoscopy, S. Giovanni Addolorata Hospital, 00184 Rome, Italy.
  • Microscopic and Ultrastructural Anatomy Research Unit Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

ORCID-Profile: Manuele Gori, Simone Di Cola, Cristiano Pagnini, Simone Carotti, Giuseppe Perrone, Ricard Farré

Förderung

  • Takeda (Italy)
  • Takeda Italia S.p.A.

Zitieren

APA

Cicala, M., Gori, M., Balestrieri, P., Altomare, A., Tullio, A., Di Cola, S., Dejongh, S., Graziani, M. G., Pagnini, C., Carotti, S., Perrone, G., Ribolsi, M., Fiorani, M., Guarino, M. P. L., & Farré, R. (2024). Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115817

Vancouver

Cicala M, Gori M, Balestrieri P, Altomare A, Tullio A, Di Cola S, et al. Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115817

BibTeX
@article{Cicala2024,
  author = {Cicala, Michele and Gori, Manuele and Balestrieri, Paola and Altomare, Annamaria and Tullio, Alessandro and Di Cola, Simone and Dejongh, Sander and Graziani, Maria Giovanna and Pagnini, Cristiano and Carotti, Simone and Perrone, Giuseppe and Ribolsi, Mentore and Fiorani, Marcello and Guarino, Michele P L and Farré, Ricard},
  title = {Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25115817}
}
Kostenlos starten →